欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - Имунологични средства за суици - Прасета - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

zoetis belgium - bedinvetmab - Аналгетици - Кучета - for the alleviation of pain associated with osteoarthritis in dogs.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - Пиле - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - Имунологични средства за еднокопитни животни - Коне - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

orion corporation - tasipimidine sulfate - Други хипнотици и успокоителни - Кучета - alleviation of situational anxiety and fear in dogs triggered by e. travel, noise, owner departure, veterinary visits.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - ламивудин - Хепатит В, хроничен - Антивирусни средства за системно приложение - zeffix is indicated for the treatment of chronic hepatitis b in adults with: , compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active liver inflammation and / or fibrosis. Начало лечение ламивудином трябва да бъдат само в случай, че използването на алтернативни антивирусни агенти с по-висок генетичен бариера не са достъпни или подходящи;, декомпенсированной заболяване на черния дроб в съчетание с втория агент, без кръстосана резистентност към ламивудину.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

recordati rare diseases - osilodrostat фосфат - Синдром на cushing - Кортикостероиди за системна употреба - isturisa се предписват за лечение на ендогенен синдром на Кушинг при възрастни.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - Множествена склероза - Селективни имуносупресори - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

astrazeneca ab - olaparib - Овариални неоплазми - Антинеопластични средства - Яйчниците cancerlynparza включен като монотерапии за:подкрепа на лечение на възрастни пациенти с късни (фиго етапи iii и iv) в гените brca1/2-мутирали (зародышевой линия и/или соматични) высокосортная епител на яйчника, маточната тръба или начална перитонеална рак, които в отговор (пълна или частична) след приключване на първа линия на базата на платина химиотерапия. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 и 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. Пациентите трябва предварително са обработени с антрациклина и таксана в (нео)помощните или метастатический, ако пациентите не са подходящи за тези процедури (виж раздел 5. Пациентите с рецептор хормон (ч)-положителен рак на гърдата трябва също така да развиват или след предварителна хормонална терапия, или се считат за неподходящи за ендокринна терапия. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - Пурпура, Тромбоцитопения, Идиопатична - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 и 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 и 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.